Thiooctylglucoside | 135969-77-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Thiooctylglucoside
• 英文别名: n-octylthioglucoside；octyl thioglucoside；(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-octylsulfanyloxane-3,4,5-triol；(2R,3S,4S,5R)-2-(hydroxymethyl)-6-octylsulfanyloxane-3,4,5-triol
• CAS: 135969-77-6
• 化学式: C₁₄H₂₈O₅S
• 分子量: 308.439
• InChiKey: CGVLVOOFCGWBCS-RQICVUQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Thiooctylglucoside 生成 1-octylthio-1-deoxy-D-glucitol
  参考文献：
  名称：

  Dahlhoff, Wilhelm V., Liebigs Annalen der Chemie, 1990, # 10, p. 1025 - 1027

  摘要：

  DOI：
• 作为产物：
  描述：

  n-octyl 2,3,4,6-tetra-O-acetyl-1-thio-D-glucopyranoside 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 Thiooctylglucoside
  参考文献：
  名称：

  Dahlhoff, Wilhelm V., Liebigs Annalen der Chemie, 1990, # 10, p. 1025 - 1027

  摘要：

  DOI：

文献信息

• [EN] DETECTION OF MYCOBACTERIA<br/>[FR] DÉTECTION DE MYCOBACTÉRIES
  申请人：ISIS INNOVATION

  公开号：WO2011030160A1

  公开（公告）日：2011-03-17

  A method for determining the presence of mycobacteria species in an organism or biological sample, the method comprising adding to the organism or biological sample a probe molecule comprising a substrate and a label, which probe molecule can be incorporated into mycobacteria, the presence of mycobacteria being determined by a detector responsive to the presence of the label, optionally after applying a stimulus; suitable probe molecules include compounds comprising a label and a substrate, which label is can be detected by a detector responsive to the presence of the label, optionally after applying a stimulus, characterised by compound being able to engage with the active site of Antigen 85B (Ag85B) such that it can form simultaneous hydrogen bonds with two or more amino acids in the active site selected from Arg 43, Trp 264, Ser126, His 262 and Leu 42, or the corresponding amino acids in Antigen 85A (Ag85A) or Antigen 85C (Ag85C), at least one of which is with Ser126.

  一种用于确定生物体或生物样本中结核分枝杆菌种类存在的方法，该方法包括向生物体或生物样本中添加一种探针分子，该探针分子包括底物和标记，该探针分子可以被结核分枝杆菌所吸收，通过对标记的存在做出反应的探测器确定结核分枝杆菌的存在，可选地，在施加刺激后进行；适用的探针分子包括包含标记和底物的化合物，该标记可以被对标记的存在做出反应的探测器检测到，可选地，在施加刺激后进行，其特征在于该化合物能够与抗原85B（Ag85B）的活性位点结合，从而能够与所选活性位点中的两个或更多氨基酸同时形成氢键，所选活性位点包括Arg 43、Trp 264、Ser126、His 262和Leu 42，或者抗原85A（Ag85A）或抗原85C（Ag85C）中对应的氨基酸，其中至少一个与Ser126形成氢键。
• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS
  申请人：Philippe Michel

  公开号：US20100028280A1

  公开（公告）日：2010-02-04

  The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

  该发明涉及一种直发角蛋白纤维的拉直过程，包括：(i)将至少两种变性剂含有的拉直组合物涂抹到角蛋白纤维上的步骤，(ii)使用加热装置将角蛋白纤维的温度升高至110至250°C的步骤。
• AMPHIPHILIC COMPOUNDS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20130266656A1

  公开（公告）日：2013-10-10

  Bringing membrane proteins into aqueous solution generally requires the use of detergents or other amphiphilic agents. The invention provides a new class of amphiphiles, each of which includes a multi-fused ring system as a lipophilic group. These new amphiphiles confer enhanced stability to a range of membrane proteins in solution relative to conventional detergents, leading to improved structural and functional stability of membrane proteins, including integral membrane proteins. Accordingly, the invention provides new amphiphiles for biochemical manipulations and characterization of membrane proteins. These amphiphiles display favorable behavior with membrane proteins and can be used to aid the solubilization, isolation, purification, stabilization, crystallization, and/or structural determination of membrane proteins.

  将膜蛋白引入水溶液通常需要使用洗涤剂或其他两性分子试剂。该发明提供了一类新型两性分子，每种都包括一个多融合环系统作为亲脂基团。这些新型两性分子相对于传统洗涤剂在溶液中赋予了一系列膜蛋白增强的稳定性，从而提高了膜蛋白的结构和功能稳定性，包括整合膜蛋白。因此，该发明提供了用于生化操作和膜蛋白表征的新型两性分子。这些两性分子与膜蛋白表现出良好的行为，并可用于辅助膜蛋白的溶解、分离、纯化、稳定化、结晶和/或结构测定。
• [EN] ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS<br/>[FR] ÉLIMINATION DU VIRUS DE L'HÉPATITE B PAR DES AGENTS ANTIVIRAUX
  申请人：UNIV EMORY

  公开号：WO2017156255A1

  公开（公告）日：2017-09-14

  The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

  本发明涉及用于预防、治疗或治愈人类或其他动物宿主体内乙型肝炎（HBV）感染的化合物、组合物和方法。这些化合物还包括作为药用的可接受的盐、前药和其他衍生物，以及用于治疗、预防或根除HBV感染的药物组合物和方法。